ARS Pharmaceuticals Inc
SPRY13.060USD
+2.110+19.27%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
1.29BMarket Cap
LossP/E TTM
More Details of ARS Pharmaceuticals Inc Company
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
ARS Pharmaceuticals Inc Info
Ticker SymbolSPRY
Company nameARS Pharmaceuticals Inc
IPO dateDec 04, 2020
CEOLowenthal (Richard E)
Number of employees155
Security typeOrdinary Share
Fiscal year-endDec 04
Address11682 El Camino Real, Suite 300
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18587719307
Websitehttps://ars-pharma.com/
Ticker SymbolSPRY
IPO dateDec 04, 2020
CEOLowenthal (Richard E)
Company Executives of ARS Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-1143342.00%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-556658.00%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-2969.00%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Saqib Islam, J.D.
Mr. Saqib Islam, J.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric Karas
Mr. Eric Karas
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-1143342.00%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-556658.00%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-2969.00%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: 20 hours ago
Updated: 20 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
10.99%
OrbiMed Advisors, LLC
8.39%
Deerfield Management Company, L.P.
7.59%
Lowenthal (Richard E)
6.91%
Pratik Shah Living Trust
4.88%
Other
61.25%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
10.99%
OrbiMed Advisors, LLC
8.39%
Deerfield Management Company, L.P.
7.59%
Lowenthal (Richard E)
6.91%
Pratik Shah Living Trust
4.88%
Other
61.25%
Shareholder Types
Shareholders
Proportion
Hedge Fund
22.26%
Investment Advisor/Hedge Fund
19.62%
Investment Advisor
16.53%
Venture Capital
15.19%
Individual Investor
11.94%
Private Equity
8.39%
Corporation
4.88%
Research Firm
3.80%
Insurance Company
0.59%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
392
85.62M
86.61%
-10.63M
2025Q3
381
87.74M
88.78%
-2.41M
2025Q2
367
96.00M
97.76%
-11.66M
2025Q1
380
100.63M
102.48%
-12.75M
2024Q4
345
96.62M
99.42%
-14.07M
2024Q3
320
88.19M
90.90%
-18.52M
2024Q2
291
87.17M
89.94%
-20.35M
2024Q1
289
89.45M
92.60%
-16.44M
2023Q4
280
92.18M
96.08%
-6.49M
2023Q3
283
95.82M
104.35%
+1.21M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
10.86M
10.99%
--
--
Sep 30, 2025
OrbiMed Advisors, LLC
8.29M
8.39%
--
--
Sep 30, 2025
Deerfield Management Company, L.P.
7.50M
7.59%
-106.41K
-1.40%
Sep 30, 2025
Lowenthal (Richard E)
6.83M
6.91%
-1.14M
-14.34%
Mar 31, 2025
Pratik Shah Living Trust
4.82M
4.88%
--
--
Mar 31, 2025
Tanimoto (Sarina)
4.57M
4.63%
-556.66K
-10.85%
Mar 31, 2025
Rubric Capital Management LP
4.50M
4.55%
+3.21M
+247.52%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.35M
4.4%
+419.68K
+10.68%
Sep 30, 2025
SR One Capital Management, LP
4.01M
4.06%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
3.49M
3.53%
+237.63K
+7.31%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ALPS Medical Breakthroughs ETF
0.38%
State Street SPDR S&P Biotech ETF
0.32%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
VictoryShares US Small Mid Cap Value Momentum ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.11%
Principal U.S. Small-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares US Small-Cap Equity Factor ETF
0.05%
iShares Biotechnology ETF
0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.04%
View more
ALPS Medical Breakthroughs ETF
Proportion0.38%
State Street SPDR S&P Biotech ETF
Proportion0.32%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.16%
VictoryShares US Small Mid Cap Value Momentum ETF
Proportion0.16%
ProShares Ultra Nasdaq Biotechnology
Proportion0.11%
Principal U.S. Small-Cap ETF
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
iShares US Small-Cap Equity Factor ETF
Proportion0.05%
iShares Biotechnology ETF
Proportion0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of ARS Pharmaceuticals Inc?
The top five shareholders of ARS Pharmaceuticals Inc are:
RA Capital Management, LP holds 10.86M shares, accounting for 10.99% of the total shares.
OrbiMed Advisors, LLC holds 8.29M shares, accounting for 8.39% of the total shares.
Deerfield Management Company, L.P. holds 7.50M shares, accounting for 7.59% of the total shares.
Lowenthal (Richard E) holds 6.83M shares, accounting for 6.91% of the total shares.
Pratik Shah Living Trust holds 4.82M shares, accounting for 4.88% of the total shares.
RA Capital Management, LP holds 10.86M shares, accounting for 10.99% of the total shares.
OrbiMed Advisors, LLC holds 8.29M shares, accounting for 8.39% of the total shares.
Deerfield Management Company, L.P. holds 7.50M shares, accounting for 7.59% of the total shares.
Lowenthal (Richard E) holds 6.83M shares, accounting for 6.91% of the total shares.
Pratik Shah Living Trust holds 4.82M shares, accounting for 4.88% of the total shares.
What are the top three shareholder types of ARS Pharmaceuticals Inc?
The top three shareholder types of ARS Pharmaceuticals Inc are:
RA Capital Management, LP
OrbiMed Advisors, LLC
Deerfield Management Company, L.P.
RA Capital Management, LP
OrbiMed Advisors, LLC
Deerfield Management Company, L.P.
How many institutions hold shares of ARS Pharmaceuticals Inc (SPRY)?
As of 2025Q4, 392 institutions hold shares of ARS Pharmaceuticals Inc, with a combined market value of approximately 85.62M, accounting for 86.61% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.16%.
What is the biggest source of revenue for ARS Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for ARS Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
